Potential Roles of Adropin in Central Nervous System: Review of Current Literature by Shima Shahjouei et al.
REVIEW
published: 27 June 2016
doi: 10.3389/fmolb.2016.00025
Frontiers in Molecular Biosciences | www.frontiersin.org 1 June 2016 | Volume 3 | Article 25
Edited by:
Megha Agrawal,
University of Illinois at Chicago, USA
Reviewed by:
Alireza Noorian,
Kaiser Permanente Orange County
Stroke Program, USA
Leili Shahgholi,
University of Florida, USA
Bardia Nourbakhsh,
University of California, San Francisco,
USA
*Correspondence:
Ramin Zand
rzand@uthsc.edu
Specialty section:
This article was submitted to
Molecular Diagnostics,
a section of the journal
Frontiers in Molecular Biosciences
Received: 21 March 2016
Accepted: 27 May 2016
Published: 27 June 2016
Citation:
Shahjouei S, Ansari S,
Pourmotabbed T and Zand R (2016)
Potential Roles of Adropin in Central
Nervous System: Review of Current
Literature. Front. Mol. Biosci. 3:25.
doi: 10.3389/fmolb.2016.00025
Potential Roles of Adropin in Central
Nervous System: Review of Current
Literature
Shima Shahjouei 1, Saeed Ansari 2, Tayebeh Pourmotabbed 3 and Ramin Zand 2, 4*
1Department of Neurosurgery, Tehran University of Medical Sciences, Tehran, Iran, 2Department of Neurology, University of
Tennessee Health Science Center, Memphis, TN, USA, 3Department of Microbiology, Immunology, and Biochemistry,
University of Tennessee Health Science Center, Memphis, TN, USA, 4 Biocomplexity Institute, Virginia Polytechnic Institute
and State University, Blacksburg, VA, USA
Adropin is a 4.9 kDa peptide that is important for maintenance of metabolic and
non-metabolic homeostasis. It regulates glucose and fatty acid metabolism and is
involved in endothelial cell function and endothelial nitric oxide (NO) synthase bioactivity
as well as physical activity and motor coordination. Adropin is expressed in many
tissues and organs including central nervous system (CNS). This peptide plays a
crucial role in the development of various CNS disorders such as stroke, schizophrenia,
bipolar disorder as well as Alzheimer’s, Parkinson’s, and Huntington’s diseases. In this
comprehensive review, the potential roles of adropin in cellular signaling pathways that
lead to pathogenesis and/or treatment of CNS disorders will be discussed.
Keywords: adropin, neurodegenerative disease, neuroprotection, biomarker, predictor, therapeutic, cellular
signaling pathways
INTRODUCTION
Adropin is a 4.9 kDa peptide encoded by Energy Homeostasis Associated gene (Enho) located on
chromosome 9 (Kumar et al., 2008; Aydin, 2014). A variety of organs including central nervous
system (neurons, neuroglial cells, pia mater, vascular area, Purkinje cells, and granular layer), heart,
kidney, liver, pancreas, and human umbilical vein synthesize adropin (Lovren et al., 2010; Aydin
et al., 2013, 2014).
Constantly new functions for adropin are identified. Adropin’s function as a regulator of glucose
and lipid homeostasis and insulin sensitivity was initially described in 2008 by Kumar et al. (2008)
and later by Aydin (2014). Lovren et al. (2010) demonstrated the endothelial protective potentials
of adropin in 2010. Adropin activates vascular endothelial growth factor receptor 2 (VEGFR2) and
its two downstream signaling pathways—phosphatidylinositol-3 kinase/ serine, threonine kinase
(PI3K/Akt) and extracellular signal-regulated kinases 1/2 (ERK 1/2) (Figure 1). Therefore, adropin
modulates expression of endothelial nitric oxide synthase (eNOS) (Lovren et al., 2010). Also,
adropin increases the endothelial cells proliferation, migration and potential to form capillary-
like structures (Lovren et al., 2010). Recently, it is found that adropin reduces the endothelial
permeability (Lovren et al., 2010; Yang et al., 2016).
Adropin enhances mitochondrial function and activates pyruvate dehydrogenase (PDH)—a
rate-limiting enzyme in glucose oxidation. Further, adropin suppresses two key enzymes in fatty
acid utilization: carnitine palmitoyltransferase-1B (CPT-1B) and Cluster of Differentiation 36
(CD36) (Gao et al., 2015); thus, it plays a role in fatty acid oxidation.
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Adropin may act as a potential protective regulator of
atherogenesis and cardiovascular diseases (Wu et al., 2014; Zhao
et al., 2015b; Li et al., 2016). Serum adropin level is inversely
associated with severity of coronary atherosclerosis and serum
level of homocysteine—a potential risk factor for atherosclerosis
and cardiovascular diseases (Zhao et al., 2015a). The serum
adropin level is diminished in patients with cardiac syndrome
X and stable coronary artery disease (Celik et al., 2013; Zhao
et al., 2015b). At the onset of acute myocardial infarction, serum
adropin level is usually lower than controls (Yu et al., 2014);
however, it raises between 1 and 24 h following myocardial
infarction (Aydin et al., 2014). Plasma adropin level has a positive
association with severity of heart failure and negative correlation
with left ventricular ejection fraction (Lian et al., 2011). Low
level of plasma adropin is predictive of pseudoexfoliation (Og˘urel
et al., 2016), coronary slow flow phenomenon (Demircelik and
Kurtul, 2015), saphenous vein graft occlusion following coronary
artery bypass grafting (Demircelik, 2014), as well as pediatric
obstructive sleep apnea in the presence of endothelial dysfunction
(Gozal et al., 2013). While Gu et al. (2015) described plasma
adropin level as an independent indicator of hypertension, other
studies failed to show this association (Altincik and Sayin, 2015).
Adropin, as a membrane-anchored protein modulates the
Notch1 signaling pathway via neural recognition molecule 3
(NB3) (Figure 1). NB-3 belongs to the contactin family and acts
as a membrane-tethered Notch1 ligand that mediates cell surface
interaction during nervous system development. An animal
study demonstrated that adropin regulates locomotor activity
and motor coordination via the NB3/Notch signaling pathway
and plays an important role in cerebellum development (Wong
et al., 2014). In this review, we discuss various roles of adropin in
central nervous system pathogenesis via different intra and extra
cellular signaling pathways as well as its therapeutic potentials.
Adropin and Vascular Endothelial Growth
Factor Receptor 2 (VEGFR2)
VEGFR2—a tyrosine kinase receptor—is especially expressed
in endothelial cells and regulates endothelial function and
angiogenesis. Adropin strongly upregulates this receptor,
activates PI3K/Akt and ERK1/2 pathways, and enhances eNOS
thus, modulating NO bioavailability (Lovren et al., 2010;
Figure 1). Hypoxic insults enhance hypoxia-inducible factor-1a
(HIF-1a), and VEGF gene expression as its downstream signaling
pathway (Mu et al., 2003). VEGF is involved in neurogenesis and
has a neuroprotection function. This has been discussed under
“Adropin and Neurogenesis” section in more details.
Role of Adropin in Activation of PI3K/Akt
Signaling Pathway
PI3K induces the phosphorylation of Akt (also known as
protein kinase B) under the effect of growth factors such as
VEGF, cytokines, insulin, and other cellular stimuli (Figure 1).
Activation of Akt requires consequent phosphorylation on Thr-
308 and Ser-473. Once Ser-473 is phosphorylated, Akt is fully
activated regardless of Thr-308 phosphorylation status (Wang
et al., 2009). Adropin can activate Akt by stimulating Ser-473
phosphorylation (Lovren et al., 2010).
Phosphorylated-Akt provokes cell cycle progression,
proliferation, differentiation, and survival (Blanco-aparicio
et al., 2007; Manning and Cantley, 2007). Moreover, this
pathway triggers intracellular ligands such as mammalian
target of rapamycin (mTOR)—which plays an important role
in angiogenesis, neuronal regeneration, synaptic plasticity,
inflammatory responses, and apoptosis (Annovazzi et al., 2009;
Chen et al., 2012; Li et al., 2015). Thereby, PI3K/Akt/mTOR
pathway may be a target of stroke therapeutic agents (Li et al.,
2015).
Neurodegenerative conditions such as Alzheimer’s,
Parkinson’s and Huntington’s diseases are associated with
defective Akt signaling (Colin et al., 2005; Griffin et al., 2005;
Timmons et al., 2009; Giralt et al., 2010). Similarly, damaged
Akt/GSK3β (the serine/threonine kinase glycogen synthase
kinase 3β) signaling pathway plays a role in the pathophysiology
of neuropsychiatric disorders such as schizophrenia and bipolar
disorders (Emamian et al., 2004; Jope, 2011). Since, variation
in AKT1—one of the three genes encoding Akt—has been
associated with schizophrenia and bipolar disorders (Ikeda et al.,
2004; Karege et al., 2012), PI3K/Akt activation by adropin might
also have a therapeutic potential in disorders such as Parkinson’s
(Burke, 2007; Timmons et al., 2009) and schizophrenia (Schwab
et al., 2005) as discussed below:
Ischemic Insult
Cerebral ischemic injuries cause neural loss secondary to
apoptosis or necrosis—which can be triggered by oxidative stress,
metabolic compromise and disruption of calcium homeostasis
at the cellular level (Mattson et al., 2001). Altintas et al.
demonstrated that infarct size is positively correlated with blood
adropin level in animal models of cerebral ischemia (Altintas
et al., 2016). Activation of Akt by adropin can prevent neuronal
and cellular death, (Chong et al., 2005) and might contribute to
neuro-protective effect of ischemic postconditioning (Gao et al.,
2008; Wang et al., 2009). PI3K/Akt pathway induces mTOR and
also attenuates apoptotic proteins such as GSK3β and forkhead
family of transcription factor. Thereby, inactivation of Akt might
contribute to neuronal apoptosis and pathogenesis of ischemic
stroke (Noshita et al., 2001; Franke et al., 2003; Hanumanthappa
et al., 2014; Li et al., 2015).
Huntington Disease (HD)
Abnormal expansion of a polyglutamine stretch in the N
terminus of protein huntingtin is responsible for neuropathology
of HD (Humbert et al., 2002). Induction of Akt Ser-473
phosphorylation attenuates mutant huntingtin toxicity and
makes the cell more resistance to apoptotic signals by modulating
proteins such as GSK3β and FOXO1 (Humbert et al., 2002;
Manning and Cantley, 2007). In addition, activated Akt decreases
intranuclear inclusions of mutant huntingtin (Humbert et al.,
2002). It was demonstrated that maintaining high levels of
activated Akt may delay cell death and allow the recovery of
neuronal viability after mutant huntingtin silencing (Canals,
2004).
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FIGURE 1 | Schematic presentation of adropin signaling pathways. PDH, pyruvate dehydrogenase; PDK-4, pyruvate dehydrogenase kinase-4; HIF-1,
hypoxia-inducible factor-1a; NB3, neural recognition molecule 3; VEGF, vascular endothelial growth factor; mhtt, mutant huntingtin; VEGFR2, vascular endothelial
growth factor receptor 2; PI3K, phosphatidylinositol-3 kinase; Akt (Ser-473), phosphorylation of serine 473 of serine, threonine kinase; GS3Kβ, glycogen synthase
kinase 3β; CD36, Cluster of Differentiation36; ERK 1/2, extracellular signal-regulated kinases 1/2; Mtor, mammalian target of rapamycin; BAD, Bcl-2 associated death
protein; eNOS (Ser-1177), phosphorylation of endothelial nitric synthase on serine 1177; BNDF, brain-derived neurotrophic factor; FOXO, Forkhead box O; Bcl-2:
B-cell lymphoma 2; Bax, Bcl-2 associated X protein; ROCK, Rho-associated protein kinase; MLC2-P, Phosphorylated myosin light chain 2.
Parkinson’s Disease (PD)
Timmons and colleagues showed that Akt is expressed at high
levels in tyrosine hydroxylase dopaminergic neurons. Selective
loss of these neurons and diminished phosphorylated Akt at Ser-
473 is obvious in the brain of patients with Parkinson’s disease
(Timmons et al., 2009). The glial cell line-derived neurotrophic
factor (GDNF) as the downstream of phosphorylated Akt has
neuroprotective effect against dopaminergic neurodegeneration
(Ries et al., 2006). Thus, medications like adropin that
target the dopaminergic system via Akt activation or those
with the potential to increase the phosphorylated Akt have
neuroprotective characteristics in PD (Ries et al., 2006; Burke,
2007; Levy et al., 2009; Timmons et al., 2009).
Schizophrenia
AKT1 gene single nucleotide polymorphisms (SNPs) and
haplotype studies indicated the involvement of Akt in
Schizophrenia (Ikeda et al., 2004; Schwab et al., 2005; Thiselton
et al., 2008). Expression or activity of AKT1 and phosphorylation
of its substrate—GSK3β—is reduced in Schizophrenic patients
(Emamian et al., 2004; Kalkman, 2006). As summarized by
Beaulieu and colleagues, many of the antipsychotics and
psychoactive substances modulate dopamine-dependent
behaviors through Akt/GSK3β signaling pathway (Beaulieu
et al., 2007). In addition, Schizophrenia is associated with insulin
receptor deficit, disruptive insulin dependent Akt signaling
and insulin resistance (Zhao et al., 2006). Adropin might be
a potent therapeutic agent in Schizophrenia while it enhances
Akt phosphorylation (Lovren et al., 2010) and prevents insulin
resistance (Ganesh Kumar et al., 2012).
Alzheimer’s Disease (AD)
Activation of PI3K/Akt/Wnt/β-catenin signaling induces
neurogenesis and reverse cognitive deficit in AD animal
models (Tiwari et al., 2015). In addition, reduced phospho-
Akt and increased FOXO3a levels in the nuclei of neurons
where proapototic genes were activated can cause adipokine
dyshomeostasis, oxidative stress, mitochondrial dysfunction, and
eventually neurodegeneration (Nuzzo et al., 2015). These data
suggest Akt might be the link between insulin resistance, obesity,
and AD.
Bipolar Disorder
Regulation of Akt/mTOR pathway is critical in synaptic
neurotransmission and plasticity, as well as modulating cell
proliferation and migration. There is evidence of excitotoxicity,
neuroinflammation, and brain atrophy in BD due to apoptosis
and disturbed synaptic function. A cadaver study on BD
postmortem prefrontal cortex demonstrated an elevation in
protein and mRNA levels of the pro-apoptotic factors (Bax, BAD,
caspase-9 and caspase-3) and reduction in anti-apoptotic factors
(BDNF and Bcl-2) and the synaptic markers (synaptophysin
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and drebrin) (Kim et al., 2010). The Bax/Bcl-2 ratio appeared
to be crucial in deciding the life or death of a cell and was
increased in the above study. In another study, blood AKT1and
mTOR mRNA expression decreased in BD during depressive
episodes comparing to healthy controls, supporting an integrated
Akt/mTOR signaling pathway activity in the pathogenesis of BD
(Machado-Vieira et al., 2015). In accordance, activation of mTOR
by N-methyl-D-aspartate (NMDA) antagonists results in rapid
antidepressant effect in animal models (Li et al., 2010).
Study on animals under high-fat diet showed that obesity
may desensitize serotonin-dependent Akt/GSK3β signaling and
impair cell proliferation in the dentate gyrus of the hippocampus,
and cause depression (Papazoglou et al., 2014). Available
evidence support the notion that enhancing the inhibitory
control of Akt/GSK3β is a key component of the therapeutic
actions of drugs used to treat mood disorders (Li and Jope, 2010).
Adropin and Extracellular Signal-Regulated
Kinases 1/2 (ERK1/2)
ERK 1/2 is a member of the mitogen-activated protein kinase
family. Adropin via VEGFR2 can activate ERK 1/2 and its
downstream cascades of substances such as brain-derived
neurotrophic factor (BDNF) (Figure 1; Lovren et al., 2010).
BNDF promotes neuronal development, differentiation, survival
and neurological function improvement following brain injury
and ischemia (Zhu et al., 2013; Zhao et al., 2014; Wu et al., 2015).
Ischemic postconditioning, both early and delayed, may further
reduce reperfusion injury via ERK 1/2 and BDNF activation (Wu
et al., 2015). In contrast, post-ischemic inhibition of ERK 1/2
in diabetic rats may mitigate DNA repairing ability, accelerated
apoptosis and aggravate neuronal loss (Zhao et al., 2014). In
addition, ERK 1/2 activation induces nuclear factor erythroid 2-
related factor2 (Nrf2) and protects neurons against beta-amyloid-
induced cell death and oxidative stress.
Adropin and Nitric Oxide Synthase (NOS)
One of the endothelial protective functions of adropin is
regulation of nitric oxide (NO) bioavailability (Lovren et al.,
2010). NO promotes angiogenesis, reparative vasculogenesis
and acts as an anti-atherosclerotic, anti-inflammatory and anti-
thrombotic factor.
NO is generated by nitric oxide synthase (NOS) that is
upregulated by PI3K/Akt and ERK 1/2 signaling pathways
(Figure 1) (Lovren et al., 2010; Peng et al., 2012). NOS
polymorphisms and diminished endothelial NOS expression
are associated with spontaneous cerebral thrombosis and
infarction, progressive cerebral amyloid angiopathy, blood brain
barrier breakdown, and cognitive impairment—characteristics
of cerebral small vessel disease, stroke and neurodegenerative
diseases such as Alzheimer’s disease (Hassan, 2004; Jeynes
and Provias, 2009; Tan et al., 2015). Additionally, Tan et al.
evidenced that this vascular occlusion occurs exclusively at the
same hypoperfused areas identified in preclinical Alzheimer’s
disease (temporoparietal and retrosplenial granular cortexes, and
hippocampus; Tan et al., 2015).
Adropin directly upregulates NOS expression in both in-
vivo and in-vitro endothelial cells resulting in proliferation,
migration, and capillary-like tube formation and diminished
permeability and apoptosis of these cells (Lovren et al.,
2010). Moreover, upregulation of NOS increases cerebral blood
flow and prevents stress-induced hypotension, inflammation,
apoptosis and cerebral ischemia (Lin et al., 2010). Thus, early
administration of nitric oxide or its precursor to patients with
acute stroke has been shown to affect lesion size, cerebral blood
flow, mood, cognition and quality of life (Willmot et al., 2005;
Woodhouse et al., 2015).
Adropin and Cluster of Differentiation 36
(CD36)
CD36 is a member of the class B scavenger receptor family and
is activated by various ligands with diverse cellular responses—
such as the production of free radicals, induction of inflammatory
responses, and endothelial dysfunction (Cho, 2005, 2012).
CD36 has anti-angiogenic nature and downregulates VEGFR2
phosphorylation, (Primo et al., 2005) and through its ligands such
as oxLDL (a major factor in the development of atherosclerosis)
causes endothelial cell stiffness and atherosclerosis (Shentu et al.,
2010). Adropin downregulates CD36 gene expression and cell
surface CD36 protein levels which indicate a potential reduction
of muscle fatty acid uptake (Gao et al., 2015). Alongside,
adropin treatment has been shown to downregulate peroxisome
proliferator-activated receptor-gamma coactivator-1α (PGC-1α)
that regulates expression of CD36 (Gao et al., 2015).
CD36 is known to be one of the underlying causes of
cerebrovascular and neurodegenerative diseases. Accumulation
of β-Amyloid (a CD36 ligand) in the vicinity of plaques
of Alzheimer’s disease, and in the cerebrovascular wall of
hemorrhagic stroke had been described (Winkler et al., 2001;
Hernandez-Guillamon et al., 2012). Increased CD36 gene
expression following blood-brain barrier damage and circulating
amyloid β protein following ischemic insult might contribute
to the pathogenesis of vascular dementia and bridge the gap
between vascular dementia and Alzheimer’s disease (Lee et al.,
2005; Ueno et al., 2016).
Adropin and Glucose Oxidation
Adropin upregulates glucose oxidation via decreasing acetylation
of pyruvate dehydrogenase complex (PDHC, a rate-limiting
enzyme in glucose oxidation) and down-regulating pyruvate
dehydrogenase kinase-4 (PDK-4)- a PDHC inhibitor. PDHC is
a mitochondrial matrix enzyme complex that catalyzes oxidative
decarboxylation of pyruvate to produce acetyl-CoA, which plays
a critical role in cerebral aerobic energy metabolism (Cardell
et al., 1989; Martin et al., 2005). Impaired cerebral energy
metabolism and PDHC activity are seen in acute brain injury
and chronic neurodegenerative conditions such as Alzheimer’s
disease and Wernicke-Korsakoff syndrome (Martin et al., 2005).
PDHC activity is attenuated after brain ischemia (Cardell
et al., 1989; Martin et al., 2005). This reperfusion dependent
suppression might be due to the depressed activity of pyruvate
dehydrogenase phosphatase or oxidative stress (because of
hyperoxic resuscitation) (Martin et al., 2005). Inactivation of
PDHC can be a possible cause of post-ischemic metabolic
depression, prolonged intracellular lactic acidosis, and secondary
Frontiers in Molecular Biosciences | www.frontiersin.org 4 June 2016 | Volume 3 | Article 25
Shahjouei et al. Potential Roles of Adropin in CNS
tissue energy depletion, which contribute to neuronal injury
and neurological impairment (Cardell et al., 1989; Martin
et al., 2005). In addition, compensating the enzyme activity by
administration of acetyl-L-carnitine which is converted to acetyl-
Co or dichloroacetate (DCA) improves neurologic outcome
(Rosenthal et al., 1992; Martin et al., 2005). Adropin treatment
in animal studies increases the ratio of CoA/acetyl-CoA which
directly promote PDHC activity and pyruvate oxidation (Gao
et al., 2015).
Adropin and Endothelial Permeability
The involvement of Adropin in endothelial permeability was
originally described by Lovren and coworkers in 2010 (Lovren
et al., 2010). Adropin attenuates the hypoxic/low glycemic
induced paracellular permeability by inhibiting ROCK/MLC2
signaling pathway (Figure 1; Yang et al., 2016). As described
by Wojciak-Stothard and Ridley, the endothelial permeability
is determined by intercellular junctions integrity and basal
intracellular actinomyosin contractility (Wojciak-Stothard and
Ridley, 2002). Rho GTPases such as Rac 1 and Rho A act
antagonistically to regulate endothelial permeability (Wojciak-
Stothard and Ridley, 2002; Wojciak-Stothard et al., 2006). Rac 1
enhances the cellular junction and adherence, (Wojciak-Stothard
et al., 2006) and inhibits Rho under chronic ischemia (Wojciak-
Stothard et al., 2005). In contrast, Rho A and its downstream
Rho-associated protein kinase (ROCK) enhance the marginal
cell isometric tension and actinomysin contractility (Wojciak-
Stothard et al., 2006). Hypoxic/hypoglycemic condition induces
activation of Rho/ROCK signaling pathway by stimulating K-
ras effector pathways independent of HIF-1 (Mizukami et al.,
2006; Wojciak-Stothard et al., 2006; Yang et al., 2016) (Figure 1).
Activated ROCK promotes direct phosphorylation of myosin
light chain 2 (MLC2) at Ser19 site and inhibition of myosin light
chain phosphatase (MLCP). Phosphorylated MLC2 enhances
actinomyosin contractility, intracellular tension and increases
cellular permeability (Yang et al., 2016). In addition, down
regulation of Rac 1 induces actin formation via Rho activation
and intensifies contractility (Wojciak-Stothard et al., 2006;
Weidemann et al., 2013).
Adropin and Neurogenesis
Induction of mesenchymal cells with inhibitors of prolyl
hydroxylase—a key enzyme in HIF-1α degradation—promotes
mesenchymal cells differentiation to morphologically neuron-
like cells (Pacary et al., 2006). HIF-1α production under
ischemic conditions induces potentially neurogenic factors—
EPO (erythropoietin), p21 and VEGF (Jin et al., 2002; Yu et al.,
2002; Pacary et al., 2006). Animal models of ischemic stroke
demonstrated functions for VEGF in neuroprotection (better
neurological outcomes and smaller infarct volume), neurogenesis
(in both early and delayed phases in neuronal precursors) and in
angiogenesis (endothelial cell proliferation, migration, survival
and vascular permeability) (Jin et al., 2001; Sun et al., 2003;
Shimotake et al., 2010). Although neurogenesis and angiogenesis
are known to be coupled, the neurotrophic potential of VEGF
might be independent of angiogenesis: VEGF induces axonal
outgrowth—by acting on growing axons and nerve cell bodies—
and suppresses the cell-death pathways mediated by calpain-
dependent and caspase-3-dependent mechanisms (Sondell et al.,
2000; Jin et al., 2001; Shimotake et al., 2010).
Recent studies demonstrated that inhibition of Rho/ROCK
signaling pathway enhances HIF-1 activity and upregulates
EPO, VEGF and p21, and consequently potentiates neurogenesis
(Pacary et al., 2007, 2008). Adropin might be a novel candidate to
promote neurogenesis as it can inhibit the Rho/ ROCK pathway
without affecting VEGF level (Yang et al., 2016).
Adropin and Orphan G Protein-Coupled
Receptor (GPR19)
Stein et al. discovered GPR19 as a potential adropin receptor
(Stein et al., 2016). GPR19 is a transmembrane receptor similar
to the neuropeptide Y receptors and the dopamine D2 receptor
family (O’Dowd et al., 1996). GPR19 is more likely expressed
in cerebellum, caudate, putamen, thalamus, hypothalamus,
hippocampus, frontal cortex and olfactory bulb (O’Dowd et al.,
1996; Hoffmeister-Ullerich et al., 2004). Transcripts of GPR19
can be detected in neuroectodermal origin tissues in early
embryogenesis, and they are gradually restricted to the regions
of the developing brain (Hoffmeister-Ullerich et al., 2004).
Signal transduction through GPR19 enhances ERK and Akt
phosphorylation in cerebral neurons (Hossain et al., 2016).
Recently, Stein et al. described the adropin function in water
intake inhibition through GPR19 (Stein et al., 2016). However,
the distribution of GPR19 and potency of its downstream
signaling pathways suggest more critical actions for adropin in
neuronal development and protection.
CONCLUSION
Studies regarding the effects of adropin in different organs
are still in infancy stage, but increasing evidence suggest that
this peptide has unique effects on endothelial cell function
via upregulating eNOS expression through the VEGFR2-PI3K-
Akt, VEGFR2-ERK 1/2 pathways and inhibition of Rho/ROCK
pathway. However, our current knowledge mainly comes
from animal studies or treatment with the putative secreted
domain of adropin. Whether these findings are transferable
to clinical studies needs to be determined. Moreover, adropin
may be utilized as a promising biomarker for CNS disease
risk stratification or diagnosis, and/or a potential therapeutic
candidate in CNS injuries. Although adropin seems to be a novel
target to limit vascular diseases, in parallel with the documented
effects on metabolic modulation, further investigations are
needed to elucidate the specific mechanism underlying the
association between adropin and CNS diseases.
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